Abstract 14806: The Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide Improve Cardiovascular and Renal Outcomes Across Most Body Mass Index Categories in Type 2 Diabetes: Results of the LEADER and SUSTAIN 6 Trials

Objective: Whether cardiorenal benefits of liraglutide and semaglutide are consistent across body mass index (BMI) categories is unknown. We performed post hoc analyses on LEADER and SUSTAIN 6 data...